Zai Lab Limited

Zai Lab earns money mainly by selling approved medicines to independent distributors, booking that revenue once a product is delivered and net of returns and rebates, alongside additional revenue from collaboration and promotional work carried out with partners. Both revenue and operating income have grown year over year for several years running, but net income has still been negative in at least some of those same years, so growing sales and improving operating results have not yet consistently turned into an overall profit.

Zai Lab scales less by producing more of one item and more by adding newly approved products and licensed programs to what it is allowed to sell in Greater China, with each addition needing its own regulatory clearance before it contributes any revenue. Where it manufactures directly, its own production lines have stated ceilings on how much they can produce in a year, so growth in those specific products depends on adding physical capacity, not on demand alone. CompanyGraph also places it among a large group of other companies that grow by clearing the same kind of regulatory approval before earning revenue on a new product.

Zai Lab depends on the global biopharmaceutical partners that license or supply the products it sells, including argenx, NovoCure, Deciphera, Innoviva, BMS, and Pfizer for specific named products, on contract manufacturers and research organizations it relies on for production and clinical trials, on its own manufacturing facilities, and on the distributors that carry its products to hospitals and patients across Greater China. It also names ongoing intellectual property protection and continued regulatory approval as things its business depends on, and its own operations and markets sit mostly in one region, Greater China. Seen at the level of whole industries, CompanyGraph separately places it as a downstream customer of a small number of supplying sectors, consistent with this picture.

Zai Lab's direct customers are the independent distributors it sells to across Greater China, who in turn reach hospitals, physicians, and patients, with third-party payors also part of that chain. The company names concentration among these distributor customers as a specific risk, and it works through named partners, including Pfizer's affiliated companies and SciClone Pharmaceuticals, to support sales of specific products in mainland China. Seen at the level of whole industries, CompanyGraph separately places it as a supplier to a number of other sectors beyond healthcare distribution itself.

Zai Lab describes its own advantages as an experienced team, partnerships with global biopharmaceutical companies, in-house research and translational capabilities, and a pipeline of proprietary candidates to which it holds global rights, along with a claimed leading position for one product by hospital sales in a specific cancer type in mainland China. CompanyGraph cannot confirm whether rivals are able to replicate these specific advantages. What it can say is that Zai Lab sits among a large group of other companies built the same way, earning revenue only after clearing a long regulatory approval process, meaning the underlying way this kind of business is run is widely shared rather than rare.

Zai Lab names regulatory approval itself as a limit on how fast it can grow, together with having enough manufacturing capacity and materials, a small number of suppliers for certain equipment and key inputs, limited in-house clinical trial capacity that makes it reliant on outside research and manufacturing organizations, and competition for qualified staff. This fits a broader pattern CompanyGraph tests across this industry, in which earning revenue depends on clearing a long approval process rather than on demand alone, though that broader pattern is a general industry expectation rather than something measured specifically for this company.

Zai Lab itself names several concentrations that could matter if something went wrong: its operations and markets sit mostly in Greater China, its own manufacturing runs through facilities in one location, two of its products are sourced exclusively from single named partners, BMS and Pfizer, and its distributor customer base is concentrated. It also flags ongoing dependence on intellectual property protection and continued regulatory approval to keep products on the market.

Zai Lab operates under named regulators in China, the United States, and Europe, and it must hold and renew manufacturing and distribution permits in mainland China to keep functioning there. It names exposure to shifting trade policy between the United States and China, including tariffs and sanctions risk, and exposure to currency controls and conversion limits affecting its renminbi earnings and holdings.